Indication

Philadelphia chromosome positive acute lymphoblastic leukemia

Philadelphia chromosome-positive acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the malignant proliferation of immature lymphoid precursor cells, primarily of B-cell lineage, within the bone marrow and peripheral blood. Read more about Philadelphia chromosome positive acute lymphoblastic leukemia

45 drugs 38 manufacturers

Advertisement

Drugs that treat it

Common Philadelphia chromosome positive acute lymphoblastic leukemia therapies.

Showing 10–18 of 45 drugs

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Major Pharamceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
DR.REDDY'S LAB

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
ASCEND LABORATO

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Hikma Pharmaceuticals USA

ICLUSIG (ponatinib HCl)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·BLASTIC PHASE CHRONIC MYELOID LEUKEMIA·+3
MILLENNIUM PHAR

IMATINIB (imatinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
ARMAS PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Philadelphia chromosome positive acute lymphoblastic leukemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Philadelphia chromosome positive acute lymphoblastic leukemia.

Philadelphia chromosome-positive acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the malignant proliferation of immature lymphoid precursor cells, primarily of B-cell lineage, within the bone marrow and peripheral blood.

It is pathologically defined by the t(9;22)(q34;q11.2) reciprocal chromosomal translocation that creates the Philadelphia chromosome, generating the oncogenic BCR::ABL1 fusion gene and producing a constitutively active tyrosine kinase that drives dysregulated cell proliferation and survival.

While occurring in both pediatric and adult populations, its incidence increases markedly with age, representing roughly one-fourth of adult cases.

Patients typically present with systemic features of bone marrow failure, including anemia, thrombocytopenia, recurrent infections, fatigue, bleeding, and potential extramedullary involvement.

Personalize your experience

Follow Philadelphia chromosome positive acute lymphoblastic leukemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it